The Foundation for Prader-Willi Research (FPWR) is presenting Harvesting Hope for PWS, a virtual “turkey trot” distance challenge to raise awareness about Prader-Willi syndrome (PWS), support research, and promote health and exercise. The nonprofit organization is encouraging supporters of all ages to log up to 100 miles walking, jogging,…
News
In a “significant subset” of children with Prader-Willi syndrome (PWS), obstructive sleep apnea worsened after the start of growth hormone therapy, a study of patients in Australia found. “Our results offer support for the current advice to perform follow-up polysomnography [sleep breathing study] in children with Prader-Willi syndrome after…
Specific epigenetic modifications — chemical marks added to DNA that affect the way genes work — are found in people with Prader–Willi syndrome (PWS), and may affect how the disease manifests, a small study reported. These findings may help in understanding how genes contribute to the disease and open…
The Prader-Willi Syndrome Association (PWSA) USA has earned a Patients at the Heart award from Harmony Biosciences. Announced Wednesday on World Narcolepsy Day, which takes place every year on Sept. 22, the award was given to the project “Disordered Sleep: A Deep Dive for Parents and Practitioners.”…
Football and science seem to be disparate fields of play at first glance, but the nonprofit Uplifting Athletes is finding common ground by leveraging the popularity of college gridiron games to fund research for rare diseases. Its nearly two dozen chapters — representing college football teams across the nation…
A new research project in Australia is investigating what underlies sleep-disordered breathing — an umbrella term for abnormal breathing patterns during sleep — often seen in children and adults with Prader-Willi syndrome (PWS). The goal, according to the researchers, is to better understand “breathing control stability” in children with…
The first healthy volunteers were dosed in a Phase 1 clinical trial evaluating Inversago Pharma‘s INV-102, a potential therapy for Prader-Willi syndrome (PWS) and other metabolic disorders. According to a company press release, the trial, underway in Canada, started dosing following a “No Objection Letter” from Health Canada.
The U.S. Food and Drug Administration (FDA) is holding a public advisory committee meeting regarding LV-101 (intranasal carbetocin) as a potential treatment of distress behaviors and insatiable hunger in Prader-Willi syndrome (PWS) patients. The Psychopharmacologic Drugs Advisory Committee meeting, to be held virtually Nov. 4 from 10…
One year of treatment with Soleno Therapeutics’ investigational oral therapy diazoxide choline controlled release, known as DCCR, significantly reduced excessive appetite and disease-related behaviors in Prader-Willi syndrome (PWS) patients, according to top-line data from an extension study of the DESTINY PWS Phase 3 trial. These trajectories were significantly…
People with Prader-Willi syndrome (PWS) have smaller pituitary glands than their typically-developing peers, according to data from a small study. The findings also suggest that altered pituitary size is associated with behavioral abnormalities in PWS. Results were published in the journal Biomarkers in Neuropsychiatry, in the study “…
Recent Posts
- Study IDs genetic subtype as possible psychosis risk factor in PWS
- We’re running our own race without the milestone charts, one win at a time
- Oxygen therapy brings sweet comfort to infants with PWS sleep apnea
- Why we said yes to adopting 2 children with Prader-Willi syndrome
- Study links age, genetic cause to quality of life in Prader-Willi syndrome
- Understanding the causes of anxiety in PWS helps to process the questions
- Vykat XR safely quiets the intense Prader-Willi hunger for years
- First participant dosed in Phase 2a trial of CSTI-500 for Prader-Willi syndrome
- Setmelanotide successfully targeting extreme hunger, obesity in PWS trial
- PWS study disputes growth hormone link to infant sleep apnea